NIH partners with industry to find best biological targets of disease
February 17th 2014The National Institutes of Health, FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
Michigan pharmacy CEO and employees indicted in $60 million fraud
February 14th 2014A federal grand jury has indicted a Michigan pharmacy CEO and several of its employees in a $60 million fraud case in which drugs previously dispensed to nursing homes and adult foster care homes were restocked and resold.
Survey: Saline shortages affecting 3 out of 4 hospitals
February 12th 2014Saline shortages are affecting three out of four hospitals and healthcare facilities throughout the country, with nearly 30% of these facilities not having adequate supplies to meet patient needs, according to a survey by the American Society of Health-System Pharmacists.
Pharmacists key to widespread HPV vaccination
February 12th 2014Millions of avoidable cancers could be prevented through widespread human papillomavirus vaccination (HPV), according to a report released by the President's Cancer Panel. And chief amongst the report’s recommendations to prevent these avoidable cancers and deaths is empowering pharmacists to administer HPV vaccinations.
FDA approves single-agent treatment for chronic lymphocytic leukemia
February 12th 2014FDA expanded the approved use of ibrutinib (Imbruvica, Pharmacyclics and Janssen Biotech) as a single agent, oral kinase inhibitor for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy.
Naproxen CV safety evidence not conclusive enough to warrant label change
February 11th 2014After examining the latest research on nonsteroidal anti-inflammatory drugs (NSAIDs)-specifically whether naproxen carries lower cardiovascular (CV) risks than ibuprofen-an FDA panel has voted down the CV safety claim for naproxen.